ADCE-T02 for Solid Tumors
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new treatment called ADCE-T02 to determine its potential benefits for people with advanced solid tumors. The goal is to identify the safest and most effective dose of ADCE-T02 when used alone. The trial targets individuals whose tumors cannot be surgically removed, have worsened after at least one other treatment, and have a life expectancy of at least three months. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that ADCE-T02 is likely to be safe for humans?
Research has shown that ADCE-T02 effectively targets tumors in various lab models. Notably, studies with animals found the experimental drug well tolerated, suggesting potential safety, though its effects in humans remain under investigation. As a phase 1 trial, the primary goal is to determine the safe dosage for humans and identify any side effects. Currently, clear information on side effects in humans is unavailable, but this trial aims to provide further insights.12345
Why do researchers think this study treatment might be promising?
Unlike standard treatments for solid tumors, which often involve chemotherapy or radiation, ADCE-T02 is unique because it targets cancer cells differently. This treatment uses a novel mechanism of action, potentially enhancing its ability to specifically target and kill tumor cells while sparing healthy tissue. Researchers are excited about ADCE-T02 because it could reduce side effects commonly associated with traditional cancer therapies, offering patients a more tolerable and possibly more effective treatment option.
What evidence suggests that ADCE-T02 might be an effective treatment for solid tumors?
Research has shown that ADCE-T02, the investigational treatment in this trial, effectively fights various solid tumors. It targets tumors with both high and low levels of a protein called tissue factor, commonly present in many cancers. In animal studies, ADCE-T02 proved safe and did not cause harmful side effects. These encouraging results suggest it could be a potential treatment for advanced solid tumors.14567
Are You a Good Fit for This Trial?
This trial is for adults with advanced solid tumors, including uterine tumors, who've had at least one systemic therapy but are still progressing. They must have a measurable lesion, be relatively fit (ECOG 0-1), expected to live more than 3 months, and have good organ function. Women of childbearing age and men must agree to use contraception during the study.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive ADCE-T02 to determine the Maximum Tolerated Dose (MTD) and safety profile
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ADCE-T02
Find a Clinic Near You
Who Is Running the Clinical Trial?
Multitude Therapeutics Inc.
Lead Sponsor
Adcendo ApS
Lead Sponsor